“a trend toward significance”

Differences were declared significant at P < 0.05 and considered a trend toward significance at 0.05 ≤ P < 0.10.

Of these 702 candidate genes, 49 were differentially regulated in treated ACH-2 cells ( p -value < 0.05 with moderated t -test; Supplementary Table S3 —labeled in green), with 21 more indicating a trend toward significance ( p < 0.1 is labelled in red).

S1 Results Additional findings that were statistically not significant, but showed a trend toward significance (0.05 < p < 0.10).

Significance was set at p < 0.05, while a trend toward significance was considered for 0.05 < p < 0.10.

In addition, there was a trend toward significance between two groups for “Staying home” ( p < 0.1), with higher score for patients with FTD.

A statistically significant group × time interaction was observed in the Oral Control subscale (F = 4.82, p = 0.0147), while a trend toward significance was noted in the Bulimia and Food Preoccupation subscale (F = 5.31, p = 0.10).

Variables showing a trend toward significance in univariate analysis ( P < 0.1) were included in a forward stepwise Cox proportional hazards regression model (entry: α = 0.05; removal: α = 0.1).

In addition to these univariate analyses, clinical outcomes were assessed using multivariate logistic regression analysis, correcting for risk factors that showed at least a trend toward significance ( p < 0.1) in the univariate analysis.

Only three colon metabolite features showed a trend toward significance ( P ≤ 0.1) in the comparisons between the control and BPA groups.

Significance was defined as P < 0.05, and a trend toward significance as 0.05 < P < 0.10.

Variables showing a trend toward significance ( p < 0.10) in univariable analysis were retained for multivariable modeling.

Variables demonstrating a trend toward significance ( p < 0.10) in the univariable analysis were entered into multivariable models using a backward stepwise approach, while age, stage, and ECOG performance status were additionally forced into the multivariable models due to their well-established clinical relevance in SCLC, and results were reported as hazard ratios (HR) with 95% confidence intervals (CI).

If the ANOVA results were statistically significant ( P < 0.05) or showed a trend toward significance ( P < 0.1), we proceeded with Fisher’s Least Significant Difference (LSD) test unless otherwise stated.

Significance was defined as P < 0.05, and a trend toward significance as 0.05 < P < 0.10.

A trend toward significance was observed for tibia values (p = 0.1), with lower injured values.

4-Penten-1-ol produced analgesia that was statistically significant before but not after correction ( t 10 = 3.0, P = 0.01), and 1-octen-3-ol produced a trend toward significance before correction ( t 11 = 1.8, P = 0.10). n -Pentyl acetate (CH 3 COO[CH 2 ] 4 CH 3 ; CAS no. 628-63-7), also known as amyl acetate, is very similar in its chemical structure to isoamyl (or isopentyl) acetate, and both are found in a variety of fruits and used to produce banana oil/extract.

Linear effects were considered significant when P ≤ 0.05 and a trend toward significance when 0.05 < P ≤ 0.10.

All reported results were considered to be significant at the p ≤ 0.05 level and were considered a trend toward significance at p ≤ 0.10.

Significant factors, and those showing a trend toward significance ( p < 0.1), in the univariate logistic analysis were entered into multivariate forward and backward logistic regression analyses.

Multivariable model was constructed considering all features that were found statistically significant ( p < 0.05) or with a trend toward significance at the univariate analysis ( p < 0.10) as independent variables and the bilateral mapping (failure/success) as the dependent variable.

All but two of the other correlations (narrow and medium stance widths at 10°), however, showed a trend toward significance (p < 0.100).

After correction for CRP, alkaline phosphatase, hemoglobin, primary EGFR mutation, and WHO performance status >1, only a trend toward significance remained for osimertinib exposure (HR 0.95, 95% CI 0.89–1.00; p = 0.10).

The BH procedure ( Benjamini and Hochberg, 1995 ) was used for multiple comparisons and treatment effects were declared significant at P < 0.05 and a trend toward significance at 0.05 ≤ P < 0.10.

Overall, the model that included genotype, smoking status, and their interaction term accounted for 9% of the variance (adjusted R 2 = 0.086, p -value <0.004) with significant main effects of smoking status (SS = 2.98, p -value <0.03) and a trend toward significance for both genotype (SS = 1.72, p -value <0.10) and the interaction term (SS = 2.15, p -value <0.07).

Differences were declared significant at P < 0.05 and a trend toward significance at 0.05 ≤ P < 0.10.